BioMarin Set Sights On Pivotal Gene Therapy Hemophilia Study

Promising early data for BioMarin’s investigational gene therapy for hemophilia, BMN 270, could suggest it could “normalize life” for patients.

Updated results from a Phase I/II of BMN 270, BioMarin’s investigative AAV5-FVIII gene transfer for hemophilia A, show that a single high dose of the gene therapy produced a 91% reduction in mean annualized bleed rates for patients who were previously treated with prophylactic Factor VIII after a follow up ranging from 34 to 50 weeks. The company plans to start a “potentially registration-enabling” Phase IIb study in the third quarter and will commission a gene therapy manufacturing facility mid-year on the back of the results.

Preliminary data from the Phase I/II study were released last July at the World Federation of Hemophilia meeting, but, as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D